Tevard Biosciences, Inc., a biotechnology company pioneering tRNA-based therapies, announced the publication of preclinical research supporting its engineered suppressor tRNA platform for Duchenne muscular dystrophy (DMD). The study, conducted by scientists at Tevard, Johns Hopkins University, MIT, and the Whitehead Institute for Biomedical Research, appears in Science Advances under the title “Engineering suppressor tRNAs for effective treatment of Duchenne Muscular Dystrophy.” The paper is available at https://doi.org/10.1126/sciadv.aeg3466.
DMD is a severe, progressive muscle-wasting disease caused by mutations in the dystrophin gene. Approximately 10-15% of DMD cases result from nonsense mutations, which introduce premature stop codons that halt dystrophin production. Current therapies are limited and mutation-specific; no treatment addresses the underlying cause for all patients. The new research describes an engineered suppressor tRNA gene therapy that targets nonsense mutations as a class, potentially offering a broader solution.
In a preclinical DMD model, the engineered suppressor tRNA therapy restored physiological levels of full-length dystrophin, improved muscle strength and motor coordination, and was well tolerated. Crucially, the engineered tRNAs targeted disease-causing nonsense mutations while leaving normal stop codons intact, demonstrating exquisite selectivity. This selectivity is a key safety feature, as indiscriminate suppression of normal stop codons could lead to harmful readthrough of essential genes.
The implications of this announcement are significant. First, it validates Tevard’s proprietary suppressor tRNA platform as a viable approach for DMD. Second, because the therapy targets nonsense mutations as a class rather than specific mutations, it could be applied to a wide range of genetic diseases caused by premature termination codons, including other muscular dystrophies, genetic cardiomyopathies, and neurological disorders such as epilepsies. Tevard is advancing a pipeline of programs spanning these areas. Third, the preclinical success provides a foundation for moving toward clinical trials, though further studies are needed to assess long-term efficacy and safety in humans.
“This publication underscores the potential of engineered suppressor tRNAs to address the root cause of DMD and other nonsense mutation-driven diseases,” said a representative of Tevard Biosciences. The company’s approach involves delivering a gene therapy that encodes a suppressor tRNA, which recognizes premature stop codons and inserts an amino acid, allowing full-length protein production. Unlike exon-skipping strategies that produce truncated dystrophin, this method aims to restore endogenous, full-length protein.
The research also highlights the collaborative effort between academic institutions and industry. Scientists from Johns Hopkins University, MIT, and the Whitehead Institute contributed to the study, combining expertise in tRNA biology, gene therapy, and muscle physiology. The publication in Science Advances, a peer-reviewed journal, adds credibility to the findings.
For patients and families affected by DMD, this news offers hope for a therapy that could treat a broader population and potentially slow or reverse disease progression. However, it is important to note that this is preclinical research; clinical trials will be necessary to determine whether the approach is safe and effective in humans. Tevard Biosciences continues to develop its pipeline and expects to advance its DMD program toward clinical development. More information about the company can be found at Tevard.com.
